CGEN — Compugen Ltd.

Compugen (CGEN) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Cash Position: As of September 30, 2025, Compugen reported approximately $86 million in cash and equivalents, with an expected cash runway extending into Q3 2027.
• Revenue: Q3 2025 revenue was approximately $1.9 million, a significant decrease from $17.1 million in Q3 2024, primarily due to the recognition of upfront and milestone payments from Gilead.
• Expenses: R&D expenses were approximately $5.8 million, down from $6.3 million in the prior year. G&A expenses were approximately $2.2 million compared to $2.6 million in Q3 2024.
• Net Loss: The company reported a net loss of approximately $6.98 million, or $0.07 per share, compared to a net profit of $1.28 million, or $0.01 per share, in the same period last year.

2. Strategic Updates and Business Highlights

• Leadership Transition: Eran Ophir has taken over as President and CEO, emphasizing a strong belief in Compugen's scientific capabilities and potential for patient impact.
• TIGIT Programs: Compugen is focusing on its Fc reduced anti-TIGIT programs, particularly COM902, which is positioned as a differentiated option in the market. The company believes that Fc reduced formats may offer better safety and efficacy compared to Fc active formats.
• Clinical Development: The ongoing MYA ovarian trial for COM701 is progressing, with interim analysis now expected in Q1 2027 due to enrollment timelines. The trial aims to demonstrate the efficacy of COM701 as a maintenance therapy in platinum-sensitive ovarian cancer.
• Partnerships: Compugen is collaborating with AstraZeneca on RILVA, a bispecific therapy, and has licensed GS0321 to Gilead, which could yield significant milestone payments and royalties.

3. Forward Guidance and Outlook

• Compugen anticipates using its cash runway to support ongoing clinical trials, including COM701 and GS0321, while continuing to invest in early-stage pipeline projects.
• The company expects to receive important data readouts from its TIGIT programs in 2026, which could serve as catalysts for growth and investor interest.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: The substantial drop in revenue year-over-year raises concerns about the company's financial health and reliance on milestone payments.
• Clinical Trial Delays: The shift of the MYA ovarian trial's interim analysis to 2027 indicates potential challenges in patient enrollment and event accumulation, which could impact timelines and investor confidence.
• Competitive Landscape: The success of competitors' Fc active anti-TIGIT programs could pose risks to Compugen's market positioning, especially if they demonstrate superior efficacy or safety.

5. Notable Q&A Insights

• Interim Analysis Timing: The delay in the MYA trial's interim analysis was attributed to site openings and enrollment rates, with management expressing confidence in meeting aggressive timelines moving forward.
• Impact of Competitor Data: The upcoming readout from Arcus Gilead's Phase III trial for an Fc reduced TIGIT antibody is seen as a critical validation point for Compugen's own programs. Management noted that even if this trial fails, Compugen has multiple avenues for success with its bispecific therapies.
• Tolerability of COM701: Management highlighted the strong tolerability profile of COM701, which is expected to facilitate its use in combination therapies, despite some grade three adverse events observed in pooled analyses.

Overall, while Compugen is navigating significant challenges, particularly in revenue and clinical timelines, its strategic focus on differentiated therapies and a solid cash position provide a foundation for potential future growth.